November/December 2013, Vol 6, No 9

Rare diseases have recently been identified as a major source of concern for health insurance companies, with some states seeking to shift a portion of the fiscal burden of orphan drugs to patients, much to patients’ concern.1 Rare diseases and orphan drugs, which have also been referred to as “orphan medicine,” “high-cost drugs,” and “rare medicine,” are subjects of increasing and intense study in pharmacoeconomics and cost-effectiveness analysis (CEA).2-4 By current estimates, between 25 million and 30 million Americans (8%-10% of the US population) have 1 of the more than 6800 diseases deemed rare, because they affect less than 200,000 people, which is the threshold used to define a “rare disease.”5

Breakthrough Therapy, or Breakthrough Pricing?

Chronic disease is responsible for 7 of 10 deaths in the United States and 75% of the nation’s $2.2- trillion healthcare bill.1,2 According to the American Diabetes Association, nearly 26 million Americans have diabetes, and more than 200,000 die of this chronic disease annually. Patients with diabetes are at increased risk for diabetes-related complications, includ­ing heart disease, stroke, kidney failure, blindness, and lower-limb amputations.3

Rosacea is a chronic skin disease that often requires continuous treatment, but data about healthcare utilization and the costs associated with its management have been lacking, especially for relatively newer therapies. James D. Kendall, PharmD, and Norman J. Preston, PhD, of Galderma Laboratories, LP, recently addressed this information gap in a poster presentation at the 2013 Academy of Managed Care Pharmacy Nexus meeting.1/P

Pulmonary arterial hypertension (PAH) is a chronic, debilitating, and life-threatening disease of the pulmonary vasculature characterized by remodeling of the small pulmonary arteries. The estimated prevalence of PAH in the United States is 12.4 cases per 1 million people, with an annual incidence of 2.3 cases per 1 million.1 Although these figures suggest that the disease is relatively rare, the societal impact is significant; morbidity and mortality rates for patients with PAH are high, and high-cost hospital stays are common.

Diabetic retinopathy is a retinal vascular disorder that affects more than 4.1 million people in the United States. New methods of detecting and ensuring adequate follow-up of this life-altering disease are vital to improving patient outcomes. Wills Eye Hospital and the Centers for Disease Control and Prevention are conducting a collaborative study to initiate a novel diabetic retinopathy screening in the community setting.
Screening for Diabetic Retinopathy in the Community Setting: Exploring the Options

Pain is a global health problem that affects 1 of 5 adults in the community1 and occurs in 43% to 77%2-4 of the approximate 35.1 million patients who are hospitalized annually in the United States.5 Pain is ubiquitous among the nearly 30.2 million people who undergo inpatient surgery annually in the United States.5 Opioid analgesics are a mainstay of postsurgical pain management,6 but are often associated with treatment-limiting gastrointestinal (GI), central nervous system, and respiratory adverse events (AEs).7 Of these, opioid-related GI AEs are the most common,8-10 with an incidence rate of 10% to 32% for nausea and/or vomiting and 15% to 41% for constipation.7,11-14 These GI AEs are particularly troublesome after surgery, because they can exacerbate anesthesia-induced nausea and decreased GI motility, sometimes resulting in ileus.7 Furthermore, GI AEs are associated with increased healthcare resource utilization because of additional medications used to manage the GI AEs and an increase in hospital length of stay (LOS).7,10,15-17

Can Substituting Generic Drugs with Brand-Name Agents for Acute Pain Postsurgery Help to Deliver Cost-Effective, Quality Care?

When nearly a score of experts get together to decipher what it means to “practice” population-based health, we ought to pay attention. That is exactly what the Advisory Board Company in Washington, DC, did this past summer. After their Population Health Leading Lights Summit, the Advisory Board Company issued a list of 8 insights that I believe are truly worth repeating.1

The Affordable Care Act (ACA) is the law of the land, but its implementation so far has been fraught with serious problems. The initial launch of was a disaster. It is unclear whether the Centers for Medicare & Medicaid Services (CMS) or the office of the Department of Health and Human Services Secretary told the White House that the October 1 deadline for the launch was not doable or highly risky, or if anyone suggested a delay.

Results 1 - 8 of 8
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME